A detailed history of C M Bidwell & Associates LTD transactions in Fate Therapeutics Inc stock. As of the latest transaction made, C M Bidwell & Associates LTD holds 30 shares of FATE stock, worth $49. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Previous 30 -0.0%
Holding current value
$49
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$4.76 - $6.59 $116,991 - $161,969
-24,578 Reduced 99.88%
30 $0
Q1 2023

May 11, 2023

BUY
$4.24 - $11.12 $103,790 - $272,206
24,479 Added 18975.97%
24,608 $140,000
Q4 2022

Feb 10, 2023

BUY
$9.86 - $23.83 $976 - $2,359
99 Added 330.0%
129 $1,000
Q1 2022

Apr 29, 2022

BUY
$29.67 - $60.28 $890 - $1,808
30 New
30 $1,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track C M Bidwell & Associates LTD Portfolio

Follow C M Bidwell & Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on C M Bidwell & Associates LTD with notifications on news.